Harpreet Singh: Can We, and Should We, Intervene Earlier in Multiple Myeloma?
Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn:
“Can we, and should we, intervene earlier in multiple myeloma?
In this episode of CMO Confidential, I break down the FDA’s latest Oncologic Drug Advisory Committee (ODAC) meeting on daratumumab (Darzalex Faspro) for smoldering multiple myeloma, a precursor state to active myeloma.
The 6-2 ODAC vote in favor of the drug’s benefit-risk profile could pave the way for the first-ever approved therapy for patients with smoldering myeloma, a meaningful step forward in how we think about early intervention.
This vote wasn’t without complexity. The trial’s evolving diagnostic criteria and endpoint selection prompted thoughtful debate, but ultimately, experts like Dr. Ken Anderson emphasized the opportunity to establish a new standard of care and build a framework for future trials in high-risk patients.
If approved, this would mark a precedent-setting regulatory decision that has the potential to reshape the treatment paradigm for multiple myeloma.
Watch this special edition of CMO Confidential for the full breakdown.”
Proceed to the video attached to the post.
More posts Featuring Harpreet Singh in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023